MSI-H/ MMRd
Quiénes somos
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC
ZN-c3 in Adult Participants With BRAF mutant Metastatic Colorectal Cancer
Un estudio de ametumumab en combinación con un anticuerpo monoclonal anti-PD-1 y FOLFIRI en pacientes con cáncer colorrectal avanzado de tipo RAS salvaje
Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung
A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver
Estudio de fase I/II del régimen de inmunoterapia combinada: SX-682, Vacuna TriAdeno, Retifanlimab y Agonista de IL-15 N-803 (STAR15) para el Cáncer Colorrectal Metastásico (CCRm).
Estudio para evaluar INCB099280 en participantes con tumores sólidos seleccionados que no han recibido ningún inhibidor de los puntos de control inmunitarios.
